Conv. Plasma
Nigella Sativa
Nitric Oxide
Peg.. Lambda

Home   COVID-19 treatment studies for Hydroxychloroquine  COVID-19 treatment studies for HCQ  C19 studies: HCQ  HCQ   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality 68% Improvement Relative Risk Ashraf et al. HCQ for COVID-19 EARLY TREATMENT Is early treatment with HCQ beneficial for COVID-19? Retrospective 100 patients in Iran Lower mortality with HCQ (not stat. sig., p=0.15) Ashraf et al., medRxiv doi:10.1101/2020.04.20.20072421.t Favors HCQ Favors control
COVID-19 in Iran, a comprehensive investigation from exposure to treatment outcomes
Ashraf et al., medRxiv doi:10.1101/2020.04.20.20072421.t (Preprint)
Ashraf et al., COVID-19 in Iran, a comprehensive investigation from exposure to treatment outcomes, medRxiv doi:10.1101/2020.04.20.20072421.t (Preprint)
Apr 2020   Source   PDF  
  All Studies   Meta
Small limited trial with 100 patients concluding that HCQ improved clinical outcome, OR 0.016 [0.002-0.11] in regression analysis.
risk of death, 67.5% lower, RR 0.32, p = 0.15, treatment 10 of 77 (13.0%), control 2 of 5 (40.0%), NNT 3.7.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Ashraf et al., 24 Apr 2020, retrospective, database analysis, Iran, preprint, median age 58.0, 16 authors, dosage 200mg bid daily, 400mg qd was used when combined with Lopinavir-Ritonavir.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperHCQAll
Abstract: Preprint: Please note that this article has not completed peer review. COVID-19 in Iran, a comprehensive investigation from exposure to treatment outcomes CURRENT STATUS: UNDER REVIEW Mohammad Ali Ashraf Shiraz University of Medical Sciences Nasim Shokouhi Tehran University of Medical Sciences Elham Shirali Tehran University of Medical Sciences Fateme Davari-tanha Tehran University of Medical Sciences Omeed Memar Academic Dermatology and Skin Cancer Institute, Chicago, IL Alireza Kamalipour University of California San Diego Ayein Azarnoush Alborz University of Medical Sciences Avin Mabadi Iran University of Medical Sciences Adele Ossareh Shahid Beheshti University Milad Sanginabadi Tehran University of Medical Sciences Talat Mokhtari Azad Tehran University of Medical Sciences Leila Aghaghazvini Tehran University of Medical Sciences 1 Sara Ghaderkhani Tehran University of Medical Sciences Tahereh Poordast Shiraz University of Medical Sciences Alieh Pourdast Tehran University of Medical Sciences Pershang Nazemi Tehran University of Medical Sciences nazemipershang@gmail.comCorresponding Author ORCiD: 10.21203/ SUBJECT AREAS Infectious Diseases KEYWORDS Coronavirus disease 2019 (COVID-19); 2019-nCoV; SARS-CoV-2; Iran; clinical characteristics; treatment outcomes 2 Abstract Background There is a growing need for information regarding the recent coronavirus disease of 2019 (Covid-19). We present a comprehensive report of Covid-19 patients in Iran. Methods One hundred hospitalized patients with Covid-19 were studied. Data on potential source of exposure, demographic, clinical, and paraclinical features, therapy outcome, and post-discharge follow-up were analyzed. Results The median age of the patients was 58 years, and the majority of the patients (72.7%) were above 50 years of age. Fever was present in 45.2% of the patients on admission. The most common clinical symptoms were shortness of breath (74%) and cough (68%). Most patients had elevated Creactive protein (92.3%), elevated erythrocyte sedimentation rate (82.9%), lymphocytopenia (74.2 %) on admission. Lower lobes of the lung were most commonly involved, and ground-glass opacity (81.8%) was the most frequent finding in CT scans. The administration of hydroxychloroquine improved the clinical outcome of the patients. Lopinavir/ritonavir was efficacious at younger ages. Of the 70 discharged patients, 40% had symptom relapse, (8.6%) were readmitted to the hospital, and 3 patients (4.3%) died. Conclusions This report demonstrates a heterogeneous nature of clinical manifestations in patients affected with Covid-19. The most common presenting symptoms are non-specific, so attention should be made on broader testing, especially in age groups with the greatest risk and younger individuals who can serve as carriers of the disease. Hydroxychloroquine and lopinavir/ritonavir (in younger age group) can be potential treatment options. Finally, patients discharged from the hospital should be followed up because of potential symptom relapse.
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop